Drug Profile
NI 302
Alternative Names: NI-302Latest Information Update: 07 Jun 2021
Price :
$50
*
At a glance
- Originator Neurimmune Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action HD protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Huntington's disease
Most Recent Events
- 07 Jun 2021 NI 302 is in early research in Huntington's disease in Switzerland (Parenteral) (Neurimmune pipeline June 2021)
- 28 May 2021 No recent reports of development identified for research development in Huntington's-disease in Switzerland
- 27 Apr 2017 Early research in Huntington's disease in Switzerland (Parenteral)(Neurimmune pipeline)